Pasi A. Jänne, MD, PhD, of Dana-Farber Cancer Institute, summarizes a workshop he conducted on the state of the art in next-generation sequencing of lung cancer (Abstract WS 01.07).
Christine D. Berg, MD, of Johns Hopkins Medicine, discusses how increased insurance coverage should dramatically increase lung cancer screening. If done correctly—which will be a challenge—screening will help improve the prognosis of patients with lung cancer (Abstract PLEN 01.01).
Silvia Novello, MD, PhD, of the University of Turin, discusses a much-neglected aspect of lung cancer: It is not just the province of men; women are affected in great numbers as well.
James R. Jett, MD, of National Jewish Health, discusses his study of the early CDT-Lung biomarker. His hypothesis: When used in combination with low-dose CT in screening of a high-risk population, this biomarker would increase the detection of early-stage lung cancer (Abstract MINI 12.11).
Ugo Pastorino, MD, of the Istituto Nazionale dei Tumori Foundation, discusses his study, which showed that stopping smoking before or during low-dose computed tomography screening reduced overall mortality by more than 25%, a benefit that is three- to fivefold greater than this type of screening (Abstract PLEN04.07).
Jennifer King, PhD, of the Lung Cancer Alliance, gives her perspective on major themes of this year’s meeting: the stigma of lung cancer, the changing face of who is affected, early detection, and advances in immunotherapy.
